Cargando…
PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429434/ http://dx.doi.org/10.1097/01.HS9.0000976024.45927.20 |
| _version_ | 1785090712317984768 |
|---|---|
| author | Su, Guoai Hu, Kai Ke, Xiaoyan Shi, Hui Zheng, Peihao Yang, Fan Feng, Shaomei Guo, Yuelu MA, Liaxia Xue, Fei Rui, Liu Xu, Teng Fu, Zhonghua Deng, Biping |
| author_facet | Su, Guoai Hu, Kai Ke, Xiaoyan Shi, Hui Zheng, Peihao Yang, Fan Feng, Shaomei Guo, Yuelu MA, Liaxia Xue, Fei Rui, Liu Xu, Teng Fu, Zhonghua Deng, Biping |
| author_sort | Su, Guoai |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429434 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104294342023-08-17 PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA Su, Guoai Hu, Kai Ke, Xiaoyan Shi, Hui Zheng, Peihao Yang, Fan Feng, Shaomei Guo, Yuelu MA, Liaxia Xue, Fei Rui, Liu Xu, Teng Fu, Zhonghua Deng, Biping Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429434/ http://dx.doi.org/10.1097/01.HS9.0000976024.45927.20 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Su, Guoai Hu, Kai Ke, Xiaoyan Shi, Hui Zheng, Peihao Yang, Fan Feng, Shaomei Guo, Yuelu MA, Liaxia Xue, Fei Rui, Liu Xu, Teng Fu, Zhonghua Deng, Biping PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA |
| title | PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA |
| title_full | PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA |
| title_fullStr | PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA |
| title_full_unstemmed | PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA |
| title_short | PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA |
| title_sort | pb2326: outcomes of anti-cancer therapy in patients with progressive refractory/relapsed b-cell lymphoma during severe coronavirus disease 2019 (covid-19): a real-world study from china |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429434/ http://dx.doi.org/10.1097/01.HS9.0000976024.45927.20 |
| work_keys_str_mv | AT suguoai pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT hukai pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT kexiaoyan pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT shihui pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT zhengpeihao pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT yangfan pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT fengshaomei pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT guoyuelu pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT maliaxia pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT xuefei pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT ruiliu pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT xuteng pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT fuzhonghua pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina AT dengbiping pb2326outcomesofanticancertherapyinpatientswithprogressiverefractoryrelapsedbcelllymphomaduringseverecoronavirusdisease2019covid19arealworldstudyfromchina |